person · Reporting owner
Rothenberg Stephen Michael
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tyra Biosciences, Inc.TYRA · Entity 4680 | Director | May 28, 2026 | June 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tyra Biosciences, Inc.
Report date May 28, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.68 · Expires 2036-05-27 | Direct | 13,160 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 13,160 · Balance 13,160 F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2026 Filed Jun 1, 2026 20:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 13,160 | $0.00 Strike: $32.68 | $0.00 |
DisclosureSEC source: 0001193125-26-251532 · ownership.xml · derivative · entry 1 Rothenberg Stephen Michael · CIK 0002022747 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,160 Underlying: Common Stock · 13,160 shares Expires 2036-05-27 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:05 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 22,200 | $0.00 Strike: $9.25 | $0.00 |
DisclosureSEC source: 0000950170-25-080227 · ownership.xml · derivative · entry 1 Rothenberg Stephen Michael · CIK 0002022747 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,200 Underlying: Common Stock · 22,200 shares Expires 2035-05-28 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2025, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| May 07, 2024 Filed May 9, 2024 20:48 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantCommon Stock (Right to Buy) · Derivative | 37,200 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0000950170-24-057192 · ownership.xml · derivative · entry 1 Rothenberg Stephen Michael · CIK 0002022747 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,200 Underlying: Common Stock · 37,200 shares Expires 2034-05-06 F1 · derivative.exercise_date: 1/36th of the total number of shares of common stock subject to the option vest monthly following May 7, 2024, the date of grant, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.